Cargando…
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
BACKGROUND: Patients with rheumatoid arthritis (RA) are at an increased risk of developing certain cancers and infections compared with the general population. Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) are effective treatment options for RA, but limited evide...
Autores principales: | Simon, Teresa A., Boers, Maarten, Hochberg, Marc, Baker, Nicole, Skovron, Mary L., Ray, Nitesh, Singhal, Sanket, Suissa, Samy, Gomez-Caminero, Andres |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839238/ https://www.ncbi.nlm.nih.gov/pubmed/31703717 http://dx.doi.org/10.1186/s13075-019-1992-x |
Ejemplares similares
-
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009) -
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019) -
Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008) -
Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006) -
Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)